Meeting
2018 ASCO Annual Meeting
Phase1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Authors
Ravi Kumar Paluri
University of Alabama at Birmingham, Birmingham, AL
Ravi Kumar Paluri , Peng Li , Benjamin Scott Jones , Ankit Madan , Mary Jerome , Debi Miley , Jennifer Keef , Francisco Robert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02835833
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2591)
DOI
10.1200/JCO.2018.36.15_suppl.2591
Abstract #
2591
Poster Bd #
417
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase 1b, open label, single institution trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
First Author: Ankit Madan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2023 ASCO Annual Meeting
Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.
First Author: Yiqun Du
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward